Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Independent clinical trials: a commentary.

Giorgio Cocconi1

  • 1Ethics Committee, Azienda Ospedaliera Universitaria, Parma, Italy. giorgio.cocconi@tin.it

Tumori
|June 29, 2002
PubMed
Summary

Independent clinical trials face significant challenges due to increased pharmaceutical industry sponsorship and a lack of regulatory oversight. Protecting independent research is crucial for medical advancement and requires specific support initiatives.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National survey of medical choices in caring for terminally ill patients in Italy, a cross-sectional study.

Tumori·2010
Same author

Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.

Acta bio-medica : Atenei Parmensis·2008
Same author

Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.

American journal of clinical oncology·2006
Same author

Attitudes to, and practice of, unconventional medicine by physicians in Italy.

European journal of internal medicine·2005
Same author

Hepatic artery administration of docetaxel in liver metastases from breast carcinoma: a feasibility study.

Tumori·2005
Same author

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.

Cancer·2005

Area of Science:

  • Clinical research ethics
  • Regulatory affairs in medicine
  • Pharmaceutical industry oversight

Background:

  • Italian legislation incorporates good clinical practice for industry-sponsored trials but lacks provisions for independent trials.
  • The pharmaceutical industry has intensified sponsored trials, creating economic ties with researchers and institutions.
  • This has raised concerns about research freedom and potential biases in findings.

Discussion:

  • Independent trials, focused on medical advancement, risk being disadvantaged against industry-sponsored trials in patient recruitment and resource acquisition.
  • Industry-sponsored trials aim for profit through drug registration, contrasting with independent research objectives.
  • There's a need to monitor pharmaceutical company influence and ensure transparency in sponsored trials to mitigate conflicts of interest.

Key Insights:

  • Lack of regulatory parity between sponsored and independent clinical trials.
  • Economic disparities and resource scarcity disadvantage independent research.
  • Potential for conflicts of interest and compromised research integrity in industry-funded studies.

Outlook:

  • Enhanced surveillance of pharmaceutical company influence in sponsored trials is necessary.
  • Transparency regarding conflicts of interest between industry and researchers is paramount.
  • Specific support initiatives are proposed to protect and sustain independent clinical trials.

Related Experiment Videos